INTRODUCTION
Poly(ethylene glycol) (PEG) modified materials are used with remarkable success to improve protein and liposome delivery in animals as well as humans. [1, 2] The qualities that make PEG an appropriate candidate for drug/protein delivery applications include: high aqueous solubility, inexpensive to manufacture, pronounced biocompatibility, and it is a component of numerous FDA approved products. [3] The attribute that makes PEG the most commonly used polymer for use in parenteral drug delivery is its ability to extend the circulation lifetimes of therapeutics. [4, 5] PEG accomplishes this by decreasing renal clearance through increased molecular weight and by acting as a steric shield to prevent the adsorption of serum opsonins. It can also reduce the interaction energy between the particle and cells, which greatly reduces uptake by the mononuclear phagocyte system (MPS). [6] PEG's attachment to a therapeutic increase its circulation half-life, hence improving the pharmacokinetics (PK) and alters the materials biodistribution (BD). These attributes allow for prolonged therapeutic activity, increased efficacy by improving solid tumor uptake, and decreased off-target effects by reducing uptake into the MPS. [4, 7] PEG, however, is not immunologically inert. [8] Between 0.6-25% of
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healthy blood donors exhibit preexisting anti-PEG IgM, presumably due to exposure to PEG at some point in the donor's lifetime. [8, 9, 10] Moreover, a low dose of PEGylated material can initiate an immune response to generate anti-PEG IgM antibodies in various species. [9, 11, 12] It was subsequently observed that the first dose of a PEGylated material may initiate the production of anti-PEG IgM, and subsequent doses are rapidly cleared from circulation which is attributed to anti-PEG IgM binding to the PEG-shielded nanoparticle. [10] This results in the material rapidly accumulating in the liver and spleen. [11] The production of anti-PEG IgM in rats takes 3-5 days, and thus no accelerated blood clearance is observed on the initial dose of a PEGylated material. [10, 13] However, many treatment strategies require multiple doses within the time window of the accelerated blood clearance effect (3-28 days post first dose). [13, 14] In circumstances were this occurs, a therapeutic can completely lose its long circulating properties, and increased toxicity is possible due to altered biodistribution. [11, 15] A number of factors can alter or inhibit the ABC effect, including dose size, [15] therapeutic payload, [16] administration regimen, [13] and even PEG end-groups. [17] Still, many materials can initiate the ABC effect, and patients who have been previously exposed to PEG may exhibit anti-PEG IgM. Another possible method for avoiding the ABC effect is to use a polymer similar to PEG that does not result in an immune response but maintains the long circulation.
A number of other hydrophilic polymers have been reported to extend circulation times of drugs or liposomes. HPMA (poly[N-(2-hydroxypropyl) methacrylamide]), [18] [19] [20] PVP (poly(vinylpyrrolidone)), [21, 22] PMOX (poly(2-methyl-2-oxazoline)), [23, 24] PAcM (poly(Nacryloyl morpholine)), [25, 26] PDMA (poly(N,N-dimethylacrylamide)), [27] polyglycerol, [28] and polyhydroxyethylaspartic acid [29] have all demonstrated the ability to increase the circulation half-life of various materials. PVP, PMOX, PAcM, and HPMA have been investigated as polymer coatings on liposomes, however, inconsistent experimental procedures among the various papers make it difficult to compare the extent to which they extend the circulation half-lives of liposomes (Table S1 ). Though materials conjugated to these polymers other than PMOX do not exhibit as long of circulation half-lives as PEG, other favorable properties could make them a better choice for certain drug delivery applications. Advantages of other polymers can include: improved physical properties, increased functional handles for drug
loading, low viscosities and more versatile post-polymerization functionalization. [3] A handful of these polymers are currently undergoing clinical trials. [1, 30, 31] Herein, we have synthesized a panel of polymers of similar molecular weights with low polydispersity and evaluated their in vivo behavior as polymer coatings for liposomes. The polymers evaluated are PEG, PMOX, HPMA, PVP, PDMA, and PAcM. We have compared the circulation times of liposomes modified with these polymers with similar molecular weights in mice and rats under consistent experimental conditions. We have also identified a correlation between polymer viscosity and circulation half-life. Furthermore, we investigated these polymers for their ability to avoid an accelerated blood clearance phenomenon and document that PMOX induces a pronounced ABC effect while HPMA and others do not cause the ABC effect.
MATERIALS AND METHODS
General: All reagents were purchased from commercial sources and used without further purification unless otherwise noted. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- ; pore size = 5000A; flow rate = 1 mL/min) equipped with a Viscotek 302 TDA.
Fluorescence spectroscopy was measured on a FluoroLog-3 spectrofluorimeter equipped with a temperature-controlled stage (LFI-3751) with FluorEssence software (Horiba Scientific, Edison, Measurements were performed in sealed, standard 1 cm quartz cells in the reaction solvent at room temperature.
General RAFT polymerization: All RAFT polymers were synthesized by adding monomer, RAFT chain transfer agent, solvent, and AIBN, in that order, to a flame dried flask. The solvent,
RAFT agent, and molar equivalences varied by polymer, and are reported in the experimental details for each specific polymer. After 5 freeze-pump-thaw cycles the flask was backfilled with argon and stirred at 65˚C. The polymerizations were monitored by MALDI by removing a small aliquot from the reaction flask. To quench RAFT polymerizations, the solution was exposed to air and cooled in an ice bath. All polymers were purified by dialysis. Yield is reported as % mass isolated for given conversion, based on molecular weight.
General post-polymerization modification of RAFT polymers: Aminolysis of all RAFT polymers yielded thiol terminated polymers, which were then conjugated to MCC PE in situ. The general procedure for post-polymerization functionalization was as follows. Polymer was added to a flame dried flask charged with a stir bar and dissolved in either THF or DMF at 100 mg/mL.
The solution was subjected to 5 freeze-pump-thaw cycles and back filled with Ar. Propylamine was added to the solution dropwise (10 mol eq.). The reaction was stirred at room temperature for 3 hours at which point complete aminolysis was confirmed by UV-VIS spectrometry.
Without exposure to oxygen, propylamine and solvent were removed under reduced pressure.
After all liquids were removed, the flask was then backfilled with Ar. The chloroform was removed via rotary evaporation to yield a thin film, which was subjected to high vacuum overnight. The lipid film was dissolved in ethanol (300 µL) at 65˚C and added to 2.7 mL HEPES buffer (10 mM HEPES, 140 mM NaCl, pH 7.4) at 65˚C in one portion. The 
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PK and biodistribubution in rats:
Male Wistar rats were administered DiD-labeled liposomes at 10 µmol phospholipid/kg via jugular cannula in 200-300 µL HEPES buffer. After the liposome administration, the cannula was flushed with 500 µL saline including 10U/mL heparin followed by 100 µL of 50% dextrose including 500 U/mL heparin. This flushing process was performed after every blood withdrawal. At selected time points (10 min, 30 min, 90 min, 4.5 h, 24 h, and 48 h), blood was collected from the jugular vein cannula into BD Microtainer® tubes coated with lithium heparin. The blood samples were centrifuged for 5 min at 7,000 X g at 4˚C.
The supernatant was collected and analyzed by spectrofluorimetry. Each group consisted of n = 3 rats.
At 48 h after administration, animals were anesthetized with an overdose of pentabarbitol. The liver, spleen, lung, and liver, of each rat were excised and transferred into was then diluted 1:1000 in PBS-C and 100 µL was added to each well and incubated for 30 minutes at 37 ˚C. Following six washes with PBS-T, 100 µL of a tetramethylbenzidine substrate solution (Sigma Aldrich) was added to wells and incubated for 30 minutes at room temperature.
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Anti-Polymer IgM
The reaction was stopped with 100 µL of 0.5 M H 2 SO 4 and the yellow product was monitored at 450 nm (Optimax, Molecular Devices, Sunnyvale, CA). Titer was defined as the reciprocal dilution of antisera yielding an optical density twice that of background. Samples were assayed in duplicate. Data analyses were performed using GraphPad Prism .
RESULTS
Synthesis:
RAFT polymerizations were chosen for the vinyl polymers in order to achieve low polydispersity and a functional terminal handle for lipid conjugation (Scheme 1A). The selection of RAFT chain transfer agent and solvent for each polymerization were based upon previous literature reports, and proved critical for attaining low polydispersity polymers. [32] Following polymerization, RAFT endgroups were converted to thiols by aminolysis with propylamine under inert atmosphere. The free thiol end group was then either reacted with additional monomer for viscosity measurements, or MCC PE for liposome incorporation (Scheme 1B).
Unlike the RAFT polymers, PMOX was synthesized through a cationic ring-opening polymerization according to previous literature procedures. [33] The polymerization of oxazolines is commonly initiated by a variety of alkylating agents and can be terminated with a wide variety of nucleophiles. In this case, PMOX polymerizations were terminated with basic water to yield a terminal hydroxyl on the polymer. For incorporation into liposomes, hydroxylterminated PMOX was functionalized with succinyl PE via carbodiimide coupling (Scheme 1C).
In a second route, the PMOX-lipid conjugate was formed by terminating the polymerization with
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dioctadecylamine. This route yielded a polymer-lipid linkage with a tertiary amine, which is protonated and positively charged at physiological pH (Scheme 1D). (Table S1 ). [21] Stable liposomes composed of HSPC, cholesterol, polymer-lipid conjugate, and DiD were formed through an ethanol injection method followed by high pressure extrusion. All liposome solutions were passed through a sterile filter and measured by DLS prior to in vivo studies. The diameter of the various modified liposomes used in these studies was ~100 nm +/-10 nm with low polydispersity (Table 1) . 
Pharmacokinetics and Biodistribution of a single dose:
The polymer modified liposomes prepared here increase liposome circulation in mice confirming previous reports (Supporting
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Information). However the increase in circulation half-life for certain polymers was longer than had previously been reported (Table S1 ).
The were then injected one week later into animals that had received the same polymer to determine if the polymer induced the ABC effect. The ABC effect is most prominent when a small (≤0.1 mol phospholipid/kg) first dose is followed 6-8 days later by a second dose. [13] When the ABC effect is elicited, the second dose is rapidly cleared from circulation and an increased accumulation in the liver and spleen is observed. If no ABC effect is observed, the second dose of a material will exhibit a similar pharmacokinetic profile and biodistribution as did the first dose.
To initiate the ABC effect, non-labeled polymer-coated liposomes were administered to rats at a concentration of 0.1 µmol phospholipid/kg. Seven days later, DiD-labeled polymercoated liposomes were administered at 10 µmol phospholipid/kg. The concentration of liposomes in circulation was measured over a 48 hour period, at which point the animals were sacrificed and the concentration of liposomes in the liver, spleen, lung, and kidneys was determined. Liposomes without polymer and liposomes with HPMA, PVP, PDMA, and PAcM did not exhibit an ABC effect ( Table 2 ). The pharmacokinetics and biodistribution of the second dose of each of these materials were very similar to those observed for a single dose ( Figure 2 ).
As expected, liposomes modified with PEG exhibited a pronounced ABC effect.
Interestingly liposomes modified with PMOX also completely lost their long circulating character (half-life < 2 h) on the second dose and had increased accumulation in the liver and spleen ( Figure 3) . (Table 3 , Figure S3 ). It remains a mystery why some polymers induce an ABC effect and others do not.
However, it is clear that the production of IgM plays an important role in the mechanism of the ABC effect. [36] In a critical step during the PEG ABC mechanism, PEGylated materials crosslink surface receptors on B-cells, which triggers the production of anti-PEG IgM. The quantity of anti-PEG IgM produced has been shown to correlate with the extent of the ABC phenomenon. [36] Furthermore, Ishihara et. al. found that PVP nanoparticles that did not exhibit an ABC effect also did not initiate the production of anti-PVP IgM. [37] We have corroborated those PVP results in our study, and shown that the other polymers in our study that do not display an ABC effect also do not initiate an IgM response. These results suggest that the polymers that do not initiate an ABC response may not be able to efficiently bind B-cell receptors or somehow interfere with IgM production through an alternative mechanism.
The increased circulation times of polymer-coated liposomes in comparison to conventional liposomes is attributed to the ability of polymers to act as a steric shield. This ability to sterically shield the liposome surface can lead to decreased interaction with other membrane surfaces [38] and serum opsonizing factors. [39, 40] A physical parameter that is influenced by all of the interactions listed above is the intrinsic viscosity of the polymers. In fact, we observe a correlation when comparing polymer modified liposome circulation half-life and polymer viscosity ( Figure 5 ). The two polymers with the highest circulation half-lives (PEG and PMOX) also have the highest viscosity as the free polymer. The polymer molecule weights used in this study are below the size where chain entanglement is predicted to arise [43] but the polymer surface density is in the brush regime [44] where polymer-polymer interactions result in an increase in the effective viscosity of the perimembranous region. [45] Increased polymer viscosity at the bilayer aqueous interface would in theory make it more difficult for macromolecules to interact with the liposome surface hence interfere with clearance mechanism mediated by opsonins. [41] Even if polymer viscosity is not the principal reason for the increase in circulation half-life, it could be a useful screen to identify other water-soluble polymers for potential half-life extenders. This trend is also seen in polymers of the same class as observed for HPMA and PVP (Table 3) : as molecular weight increases, viscosity and circulation half-life modestly increase.
It is interesting, that the two most viscous polymers were also the two that initiated an ABC response. Thus, polymers with higher intrinsic viscosities may be more likely to induce an immune response, and our data suggests that there may be a minimum viscosity threshold for the IgM response to occur. Further investigation of the immune reactivity/B cell interaction of polymer modified liposome with viscosities greater than PEG or PMOX could shed light on this topic. We compared pharmacokinetics and biodistribution of liposomes incorporating 5 mole percent of 2 kDa polymers. These values were chosen based on previous reports of the ideal mole percent and molecular weight of PEG for extending liposome circulation. [46, 47] However, these may not be the optimal conditions for the other polymers investigated. In fact, we have shown that increasing the molecular weight of PVP and HPMA can modestly increase circulation half-lives (Table 3 ). The ideal graft density and molecular weight of polymers for the steric protection of liposomes in vivo is one that strikes a balance between providing complete surface coverage and allowing for sufficient chain mobility. [47] Because the polymers we have investigated have different chain flexibilities and degrees of polymerization, 5 mole percent and 2 kDa molecular weight may not be ideal parameters for each polymer. Polymers of optimal molecular weight and liposomal graft density may further improve the circulation half-lives, strengthening the case for their use rather than PEG in certain applications.
In this study we have evaluated the physical and in vivo properties of a panel of hydrophilic polymers for extended circulation. We have also confirmed that HPMA, PVP, PDMA and PAcM are able to extend the circulation half-lives of liposomes without eliciting the ABC effect upon repeated administration. We have found that PMOX, a polymer with very similar in vivo properties to PEG, initiates a pronounced ABC effect. Our results suggest that in specific cases where PEG's ABC effect is detrimental to a delivery system or patient's have preexisting anti-PEG antibodies [8] , other polymers can play the role of sterically stabilizing materials in vivo. These observations may assist the future design, selection and application of polymers for extended circulation and improved drug delivery.
